In this commentary, the authors report on the The Learning Collaborative experience. Following a meeting gathering , leaders from industry, government, academia, and non-profit organizations which lead to the publication of a white paper : "The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results", the Learning Collaborative, was established with foccus on :
 Repurposing Drugs for the Benefit of Patients
 Building A New Academic Model
 Advances in Regulatory Science and Public Policy

While the target population is different, the conclusions of the paper is totally in line with the aims of MGHI : "Non-traditional, dynamic partnerships, like The Learning Collaborative, allow non-profit organizations to play a high impact role in advancing the development of new cancer drug therapies and bringing these therapies rapidly to patients. The foundations of The Learning Collaborative model are a willingness to rely on partners for expertise, share freely, stay focused on the shared goal of translating discoveries from the lab to marketplace, and view deliverables as not only new treatments but also improvements in the processes by which those treatments are developed. The Learning Collaborative model allows the partner organizations to more effectively advance their missions to bring new therapies to the millions of patients suffering from rare cancers" .